Avalo Therapeutics Stock (NASDAQ:AVTX)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$9.08

52W Range

$3.95 - $34.46

50D Avg

$11.16

200D Avg

$10.99

Market Cap

$93.23M

Avg Vol (3M)

$57.92K

Beta

1.03

Div Yield

-

AVTX Company Profile


Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

19

IPO Date

Oct 14, 2015

Website

AVTX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
License$516.00K$14.69M$625.00K
Product$1.41M$3.36M$4.77M

Fiscal year ends in Dec 23 | Currency in USD

AVTX Financial Summary


Dec 23Dec 22Dec 21
Revenue$1.41M$18.05M$5.40M
Operating Income$-27.87M$-37.44M$-82.13M
Net Income$-31.54M$-41.66M$-84.35M
EBITDA$-27.87M$-37.42M$-80.59M
Basic EPS$-114.00$-4.43$-9.71
Diluted EPS$-114.00$-4.43$-9.71

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
CGEMCullinan Oncology, Inc.
ANABAnaptysBio, Inc.
IPSCCentury Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
ALXOALX Oncology Holdings Inc.
PMVPPMV Pharmaceuticals, Inc.
MLYSMineralys Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
ALZNAlzamend Neuro, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
VRAXVirax Biolabs Group Limited
CCCCC4 Therapeutics, Inc.
GPCRStructure Therapeutics Inc.
BNOXBionomics Limited
ANEBAnebulo Pharmaceuticals, Inc.
BNTCBenitec Biopharma Inc.
ACLXArcellx, Inc.
MOLNMolecular Partners AG